Summary of the data concerning the possible adverse effects of prior IFN-α treatment on the outcome of alloBMT.In the IBMTR study of Giralt et al62 it was found that the patients who were pretreated with IFN-α had a slightly higher risk of non-engraftment (2% vs 0.2%, p = 0.01) and a slightly lower risk of relapse (1% vs 8%, p = 0.01).
| . | No. of Cases . | Marrow Donors . | Detectable Effects . |
|---|---|---|---|
| Abbreviations: Sib, sibling; VU, volunteer unrelated marrow donor; BMT, bone marrow transplant. | |||
| Giralt et al 1993 | 23 | SIB | None |
| Beelen et al 1995 | 50 | SIB/VU | Adverse, if treatment for more than 1 year |
| Shepherd et al 1995 | 53 | SIB/VU | None |
| Zuffa et al 1998 | 16 | SIB | None |
| Tomàs et al 1998 | 30 | SIB | None |
| Beelen et al 1999 | 94 | SIB/VU | Adverse, if treatment for more than 1 year and discontinued less than 3 months before alloBMT |
| Hehlmann et al 1999 | 86 | SIB/VU | Adverse if treatment discontinued less than 3 months before alloBMT |
| Giralt et al (IBMTR) 2000 | 209 | SIB | None |
| . | No. of Cases . | Marrow Donors . | Detectable Effects . |
|---|---|---|---|
| Abbreviations: Sib, sibling; VU, volunteer unrelated marrow donor; BMT, bone marrow transplant. | |||
| Giralt et al 1993 | 23 | SIB | None |
| Beelen et al 1995 | 50 | SIB/VU | Adverse, if treatment for more than 1 year |
| Shepherd et al 1995 | 53 | SIB/VU | None |
| Zuffa et al 1998 | 16 | SIB | None |
| Tomàs et al 1998 | 30 | SIB | None |
| Beelen et al 1999 | 94 | SIB/VU | Adverse, if treatment for more than 1 year and discontinued less than 3 months before alloBMT |
| Hehlmann et al 1999 | 86 | SIB/VU | Adverse if treatment discontinued less than 3 months before alloBMT |
| Giralt et al (IBMTR) 2000 | 209 | SIB | None |